Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1–4
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Parainfluenza virus types 1–4 (PIV1–4) are highly infectious human pathogens, of which PIV3 is most commonly responsible for severe respiratory illness in newborns, elderly, and immunocompromised individuals. To obtain a vaccine effective against all four PIV types, we engineered mutations in each of the four PIV fusion (F) glycoproteins to stabilize their metastable prefusion states, as such stabilization had previously enabled the elicitation of high-titer neutralizing antibodies against the related respiratory syncytial virus. A cryoelectron microscopy structure of an engineered PIV3 F prefusion-stabilized trimer, bound to the prefusion-specific antibody PIA174, revealed atomic-level details for how introduced mutations improved stability as well as how a single PIA174 antibody recognized the trimeric apex of prefusion PIV3 F. Nine combinations of six newly identified disulfides and two cavity-filling mutations stabilized the prefusion PIV3 F immunogens and induced 200- to 500-fold higher neutralizing titers in mice than were elicited by PIV3 F in the postfusion conformation. For PIV1, PIV2, and PIV4, we also obtained stabilized prefusion Fs, for which prefusion versus postfusion titers were 2- to 20-fold higher. Elicited murine responses were PIV type-specific, with little cross-neutralization of other PIVs. In nonhuman primates (NHPs), quadrivalent immunization with prefusion-stabilized Fs from PIV1–4 consistently induced potent neutralizing responses against all four PIVs. For PIV3, the average elicited NHP titer from the quadrivalent immunization was more than fivefold higher than any titer observed in a cohort of over 100 human adults, highlighting the ability of a prefusion-stabilized immunogen to elicit especially potent neutralization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013) · Science · doi:10.1126/science.1243283 · Cited by 1,126
Self-citationStructure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
McLellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang, Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., et al. (2013) · Science · doi:10.1126/science.1234914 · Cited by 883
Self-citationStructure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., et al. (2011) · Nature · doi:10.1038/nature10696 · Cited by 830
Self-citationNonviral delivery of self-amplifying RNA vaccines
Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 741 · cited 1×
“Although our work here focused on the use of purified recombinant proteins for vaccination, it seems likely that the prefusion designs can be utilized in genetic contexts, as has been shown for prefusion-stabilized RSV F in the context of a PIV1 vector (36) or as a mRNA vaccine (37).”
BackgroundA highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism
Krarup, A., Truan, D., Furmanova-Hollenstein, P., Bogaert, L., Bouchier, P., Bisschop, I. J. M., Widjojoatmodjo, M. N., Zahn, R., Schuitemaker, H., McLellan, J. S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9143 · Cited by 383
Cited by
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066
Self-citation(2024) · doi:10.1073/pnas.2404250121 · Cited by 37
Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes
Fedechkin, S. O., George, N. L., Nuñez Castrejon, A. M., Dillen, J. R., Kauvar, L. M., & DuBois, R. M. (2020) · Journal of Virology · doi:10.1128/jvi.01879-19 · Cited by 26
A general computational design strategy for stabilizing viral class I fusion proteins
Gonzalez, K. J., Huang, J., Criado, M. F., Banerjee, A., Tompkins, S. M., Mousa, J. J., & Strauch, E.-M. (2024) · Nature Communications · doi:10.1038/s41467-024-45480-z · Cited by 20
Metadata
- Authors
- Stewart-Jones, G. B. E., Chuang, G.-Y., Xu, K., Zhou, T., Acharya, P., Tsybovsky, Y., Ou, L., Zhang, B., Fernandez-Rodriguez, B., Gilardi, V., Silacci-Fregni, C., Beltramello, M., Baxa, U., Druz, A., Kong, W.-P., Thomas, P. V., Yang, Y., Foulds, K. E., Todd, J.-P., Wei, H., Salazar, A. M., Scorpio, D. G., Carragher, B., Potter, C. S., Corti, D., Mascola, J. R., Lanzavecchia, A., & Kwong, P. D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2018-11-12
- Volume
- 115
- Issue
- 48
- Pages
- 12265-12270
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2901328586
- Cited by
- 97
- References
- 6
- FWCI
- 5.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1–4. https://app.cochat.ai/papers/10.1073/pnas.1811980115
- The paper
- Stewart-Jones, G. B. E., Chuang, G.-Y., Xu, K., Zhou, T., Acharya, P., Tsybovsky, Y., Ou, L., Zhang, B., Fernandez-Rodriguez, B., Gilardi, V., Silacci-Fregni, C., Beltramello, M., Baxa, U., Druz, A., Kong, W.-P., Thomas, P. V., Yang, Y., Foulds, K. E., Todd, J.-P., . . . Kwong, P. D. (2018). Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1–4. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1811980115
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.